Study to Determine the Efficacy and Safety of TG-C in Subjects with Kellgren/Lawrence Grade 2 or 3 OA of the Knee

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

531

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

March 6, 2024

Study Completion Date

March 6, 2026

Conditions
Degenerative Osteoarthritis
Interventions
BIOLOGICAL

TG-C

2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1

BIOLOGICAL

Placebo Control

2 mL normal saline intraarticular injection

Trial Locations (27)

10016

Jonathan Samuels, New York

11235

Igor Grosman, Brooklyn

27704

John Solic, Durham

28412

Jeremy Hoff, Wilmington

29406

Edward Tavel, Charleston

33126

Jan Hommen, Doral

33409

Mira Baron, West Palm Beach

33756

Miguel Trevino, Clearwater

45432

Priyesh Mehta, Dayton

48307

Nathan Rimmke, Rochester Hills

60611

Thomas Schnitzer, Chicago

63141

Larkin Wadsworth, St Louis

75057

Manjoo Sharma, Lewisville

75154

Haresh Boghara, Red Oak

75230

James Lilly, Dallas

78215

Leonel Reyes, San Antonio

78229

Charles Andrews, San Antonio

83713

Richard Radnovich, Boise

85712

Nebojsa Skrepnik, Tucson

89109

Duane C Anderson, Las Vegas

90211

Stuart Silverman, Beverly Hills

91722

Samy Metyas, Covina

91942

Peter Hanson, La Mesa

92120

John Beckes, San Diego

92647

Bassil Aish, Huntington Beach

92801

Steve Sitar, Anaheim

99218

David Scott, Spokane

Sponsors
All Listed Sponsors
lead

Kolon TissueGene, Inc.

INDUSTRY